Chronic obstructive pulmonary disease is a condition caused by damage to the lungs that results in breathing difficulties.

COPD emerged as an umbrella term for several respiratory diseases, including emphysema and chronic bronchitis, caused by lung damage. Because its effects are irreversible, early diagnosis and ...

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and ...

Operator: Good morning, and welcome to the Liquidia Corporation Third Quarter 2025 Financial Results and Corporate Update ...

Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares ...

and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered ...

The resulting iron buildup after decades can cause damage to many tissues, including the heart. This can increase the rate of ...

Chronic obstructive pulmonary disease (COPD) affects approximately 29 million people in the U.S. and is the fourth leading ...

I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I’m ...

Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that affects millions of people in the United ...

Regardless of blood eosinophil count threshold, adults with COPD and an eosinophilic phenotype experienced significantly fewer moderate/severe exacerbations in a year with mepolizumab vs. placebo, ...

Using different oximeter devices for monitoring stable patients under NIV or CPAP may have an unpredictable effect on results and clinical decisions.